MIT’s cancer and infectious disease therapy spinout has added $40m to a round that will support the progression of its lead asset into the clinic.

Elicio Therapeutics, a US-based immuno-oncology therapy spinout of Massachusetts Institute of Technology (MIT), has increased its series B round to $73m. The company raised $33m for the first close of the round in October 2019 but has not confirmed the identity of any of the participants, though it said the latest funding came from an…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.